News

Zejula is a poly(ADP-ribose) polymerase (PARP) inhibitor which has to be taken orally daily once. It has been approved for the maintenance treatment of adult patients with recurrent epithelial

Antimicrobial resistance is one of the greatest threats to global human and animal health – the O’Neill Report published last year stated that, unless we take urgent action, it will

This follows an interim review of the safety and tolerability data from the ongoing trial by an independent Data Monitoring Committee ('DMC') and its support of Summit's plans

The studies have demonstrated that the sarecycline achieved the 12 week primary efficacy endpoints in the treatment of patients with moderate to severe acne. Sarecycline is a once-daily,

Ignyta had previously disclosed it was in discussions with Lilly regarding the optimal path forward for taladegib in the context of its pipeline priorities, which are focused substantially

PureTech Health will develop these new product candidates in an operating subsidiary, resTORbio, with an initial focus on diseases related to immunosenescence, an age-related decline in immune function.

The trial results could not show the topical stearoyl Co-A desaturase-1, or SCD1 inhibitor, XEN801 producing any statistically considerable difference in the primary endpoint of the percent change

Pemphigus vulgaris is a severe life-threatening condition, which can be recognized by progressive painful blistering of the skin and mucous membranes. Rituxan is a type of antibody therapy,

Amgevita is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic